Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.
CIPN
Chemotherapy-induced peripheral neuropathy
Neuropathy
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
23
01
2019
accepted:
09
07
2019
pubmed:
1
8
2019
medline:
14
11
2019
entrez:
1
8
2019
Statut:
ppublish
Résumé
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual's specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.
Identifiants
pubmed: 31363906
doi: 10.1007/s00520-019-04987-8
pii: 10.1007/s00520-019-04987-8
pmc: PMC6728179
mid: NIHMS1536077
doi:
Substances chimiques
Antineoplastic Agents
0
Taxoids
0
Vinca Alkaloids
0
Bortezomib
69G8BD63PP
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3729-3737Subventions
Organisme : NCI NIH HHS
ID : R01 CA211887
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA238946
Pays : United States
Organisme : National Institutes of Health / National Cancer Institute
ID : R01CA189947
Organisme : National Institute of Health / National Cancer Institute
ID : R01CA211887
Références
Gewandter JS, Fan L, Magnuson A et al (2013) Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer 21(7):2059–2066
doi: 10.1007/s00520-013-1766-y
pubmed: 23446880
pmcid: 3669650
Miaskowski C, Mastick J, Paul SM et al (2018) Impact of chemotherapy-induced neurotoxicities on adult cancer survivors’ symptom burden and quality of life. J Cancer Surviv 12(2):234–245
doi: 10.1007/s11764-017-0662-8
pubmed: 29159795
Seretny M, Currie GL, Sena ES et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 155(12):2461–2470
doi: 10.1016/j.pain.2014.09.020
pubmed: 25261162
Molassiotis A, Cheng HL, Leung KT et al (2019) Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 9:e01312
doi: 10.1002/brb3.1312
pubmed: 31063261
pmcid: 6576180
Bulls HW, Hoogland AI, Kennedy B et al (2019) A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer. Gynecol Oncol 152(2):310–315
doi: 10.1016/j.ygyno.2018.12.002
pubmed: 30558975
Hershman DL, Till C, Wright JD et al (2016) Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials. J Clin Oncol 34(25):3014–3022
doi: 10.1200/JCO.2015.66.2346
pubmed: 27325863
pmcid: 5012713
Raphael MJ, Fischer HD, Fung K et al (2017) Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer. Clin Colorectal Cancer 16(4):397–404 e391
doi: 10.1016/j.clcc.2017.03.013
pubmed: 28434884
Argyriou AA, Polychronopoulos P, Koutras A et al (2006) Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 14(3):223–229
doi: 10.1007/s00520-005-0868-6
pubmed: 16021477
Nurgalieva Z, Xia R, Liu CC, Burau K, Hardy D, Du XL (2010) Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. Am J Ther 17(2):148–158
doi: 10.1097/MJT.0b013e3181a3e50b
pubmed: 19417586
Cox-Martin E, Trahan LH, Cox MG, Dougherty PM, Lai EA, Novy DM (2017) Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy. Support Care Cancer 25(6):1873–1879
doi: 10.1007/s00520-017-3571-5
pubmed: 28124735
pmcid: 5439217
Schneider BP, Li L, Radovich M et al (2015) Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res 21(22):5082–5091
doi: 10.1158/1078-0432.CCR-15-0586
pubmed: 26138065
pmcid: 4717479
Starobova H, Vetter I (2017) Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci 10:174
doi: 10.3389/fnmol.2017.00174
pubmed: 28620280
pmcid: 5450696
Cao Y, Zhang G, Wang P et al (2017) Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer. BMC Gastroenterol 17(1):2
doi: 10.1186/s12876-016-0561-x
pubmed: 28056823
pmcid: 5217235
Zhang X, Jiang LP, Yin Y, Wang YD (2014) XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis. Tumor Biol 35(6):5637–5645
doi: 10.1007/s13277-014-1746-y
Savas S, Kim DY, Ahmad MF, Shariff M, Ozcelik H (2004) Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomark Prev 13(5):801–807
Whitehouse CJ, Taylor RM, Thistlethwaite A et al (2001) XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell. 104(1):107–117
doi: 10.1016/S0092-8674(01)00195-7
pubmed: 11163244
Song X, Wang S, Hong X et al (2017) Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer. Sci Rep 7(1):11785
doi: 10.1038/s41598-017-08257-7
pubmed: 28924235
pmcid: 5603542
Custodio A, Moreno-Rubio J, Aparicio J et al (2014) Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann Oncol 25(2):398–403
doi: 10.1093/annonc/mdt546
pubmed: 24351404
Johnson C, Pankratz VS, Velazquez AI et al (2015) Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J Neurol Sci 349(1–2):124–128
doi: 10.1016/j.jns.2014.12.041
pubmed: 25586538
pmcid: 4334320
Hertz D, Kidwell K, K. V, D. S, NL. H. (2017) Association of systemic paclitaxel concentrations with severity and progression of paclitaxel-induced peripheral neuropathy. San Antonio Breast Cancer Symposium. 2017.
Boora GK, Kanwar R, Kulkarni AA et al (2016) Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Cancer Med 5(4):631–639
doi: 10.1002/cam4.625
pubmed: 26763541
pmcid: 4831281
Abraham JE, Guo Q, Dorling L et al (2014) Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clin Cancer Res 20(9):2466–2475
doi: 10.1158/1078-0432.CCR-13-3232
pubmed: 24599932
Lam SW, Frederiks CN, van der Straaten T, Honkoop AH, Guchelaar HJ, Boven E (2016) Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients. Br J Cancer 115(11):1335–1342
doi: 10.1038/bjc.2016.326
pubmed: 27736846
pmcid: 5129817
Boora GK, Kulkarni AA, Kanwar R et al (2015) Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). J Neurol Sci 357(1–2):35–40
doi: 10.1016/j.jns.2015.06.056
pubmed: 26143528
pmcid: 4575633
Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK (2015) Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Acta Oncol 54(4):530–537
doi: 10.3109/0284186X.2014.969846
pubmed: 25383449
Kus T, Aktas G, Kalender ME et al (2016) Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. OncoTargets and Ther 9:5073–5080
doi: 10.2147/OTT.S106574
van Rossum AGJ, Kok M, McCool D et al (2017) Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. Oncotarget. 8(69):113531–113542
pubmed: 29371927
pmcid: 5768344
Hertz DL, Roy S, Jack J et al (2014) Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Res Treat 145(1):245–254
doi: 10.1007/s10549-014-2910-1
pubmed: 24706167
pmcid: 4256153
Stock W, Diouf B, Crews KR et al (2017) An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin Pharmacol Ther 101(3):391–395
doi: 10.1002/cpt.506
pubmed: 27618250
Wright GEB, Amstutz U, Drogemoller BI, et al. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clin Pharmacol Ther. 2018;105(2):402-410
Gutierrez-Camino A, Martin-Guerrero I, Lopez-Lopez E et al (2016) Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population. Pharmacogenet Genomics 26(2):100–102
doi: 10.1097/FPC.0000000000000191
pubmed: 26618658
Zgheib NK, Ghanem KM, Tamim H et al (2018) Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. Pharmacogenet Genomics 28(8):189–195
doi: 10.1097/FPC.0000000000000345
pubmed: 30119132
Kelley MR, Wikel JH, Guo C et al (2016) Identification and characterization of new chemical entities targeting apurinic/apyrimidinic endonuclease 1 for the prevention of chemotherapy-induced peripheral neuropathy. J Pharmacol Exp Ther 359(2):300–309
doi: 10.1124/jpet.116.235283
pubmed: 27608656
pmcid: 5074487
Kulkarni AA, Boora G, Kanwar R et al (2015) RWDD3 and TECTA variants not linked to paclitaxel induced peripheral neuropathy in North American trial Alliance N08C1. Acta Oncol 54(8):1227–1229
doi: 10.3109/0284186X.2014.985388
pubmed: 25549536
Moore AS, Norris R, Price G et al (2011) Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. J Paediatr Child Health 47(12):875–882
doi: 10.1111/j.1440-1754.2011.02103.x
pubmed: 21658147
Skiles JL, Chiang C, Li CH, et al. (2018) CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. Pediatr Blood Cancer 65(3).
Moreau P, Pylypenko H, Grosicki S et al (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431–440
doi: 10.1016/S1470-2045(11)70081-X
pubmed: 21507715
Egbelakin A, Ferguson MJ, MacGill EA et al (2011) Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56(3):361–367
doi: 10.1002/pbc.22845
pubmed: 21225912
Campo C, da Silva Filho MI, Weinhold N et al (2018) Bortezomib-induced peripheral neuropathy: a genome-wide association study on multiple myeloma patients. Hematol Oncol 36(1):232–237
doi: 10.1002/hon.2391
pubmed: 28317148
Guilhaumou R, Solas C, Bourgarel-Rey V et al (2011) Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemother Pharmacol 68(6):1633–1638
doi: 10.1007/s00280-011-1745-2
pubmed: 21968951
Favis R, Sun Y, van de Velde H et al (2011) Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics 21(3):121–129
doi: 10.1097/FPC.0b013e3283436b45
pubmed: 21228734
Magrangeas F, Kuiper R, Avet-Loiseau H et al (2016) A genome-wide association study identifies a novel locus for bortezomib-induced peripheral neuropathy in european patients with multiple myeloma. Clin Cancer Res 22(17):4350–4355
doi: 10.1158/1078-0432.CCR-15-3163
pubmed: 27060151
pmcid: 5010494
Johnson DC, Corthals SL, Walker BA et al (2011) Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 29(7):797–804
doi: 10.1200/JCO.2010.28.0792
pubmed: 21245421
Cibeira MT, de Larrea CF, Navarro A et al (2011) Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. Leuk Res 35(9):1178–1183
doi: 10.1016/j.leukres.2011.02.009
pubmed: 21435719
Gregg RW, Molepo JM, Monpetit VJ et al (1992) Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10(5):795–803
doi: 10.1200/JCO.1992.10.5.795
pubmed: 1569451
de Wit R, Roberts JT, Wilkinson PM et al (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19(6):1629–1640
doi: 10.1200/JCO.2001.19.6.1629
pubmed: 11250991
Nichols CR, Williams SD, Loehrer PJ et al (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9(7):1163–1172
doi: 10.1200/JCO.1991.9.7.1163
pubmed: 1710655
Sprowl JA, Ciarimboli G, Lancaster CS et al (2013) Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A 110(27):11199–11204
doi: 10.1073/pnas.1305321110
pubmed: 23776246
pmcid: 3704038
Hucke A, Ciarimboli G (2016) The role of transporters in the toxicity of chemotherapeutic drugs: focus on transporters for organic cations. J Clin Pharmacol 56(Suppl 7):S157–S172
doi: 10.1002/jcph.706
pubmed: 27385173
Chalret du Rieu Q, White-Koning M, Picaud L et al (2014) Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia. Cancer Chemother Pharmacol 74(3):571–582
doi: 10.1007/s00280-014-2525-6
pubmed: 25053386
Shord SS, Bernard SA, Lindley C et al (2002) Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity. Anticancer Res 22(4):2301–2309
pubmed: 12174918
Ishibashi K, Okada N, Miyazaki T, Sano M, Ishida H (2010) Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol 15(1):82–87
doi: 10.1007/s10147-009-0015-3
pubmed: 20108160
Albers JW, Chaudhry V, Cavaletti G, Donehower RC (2014) Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 3:CD005228
Schloss J, Colosimo M, Vitetta L (2016) New insights into potential prevention and management options for chemotherapy-induced peripheral neuropathy. Asia Pac J Oncol Nurs 3(1):73–85
doi: 10.4103/2347-5625.170977
pubmed: 27981142
pmcid: 5123533
Frederiks CN, Lam SW, Guchelaar HJ, Boven E (2015) Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: a systematic review. Cancer Treat Rev 41(10):935–950
doi: 10.1016/j.ctrv.2015.10.010
pubmed: 26585358
Mielke S, Sparreboom A, Steinberg SM et al (2005) Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11(13):4843–4850
doi: 10.1158/1078-0432.CCR-05-0298
pubmed: 16000582
Joerger M, von Pawel J, Kraff S et al (2016) Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 27(10):1895–1902
doi: 10.1093/annonc/mdw290
pubmed: 27502710
Agergaard K, Mau-Sorensen M, Stage TB et al (2017) Clopidogrel-paclitaxel drug-drug interaction: a pharmacoepidemiologic study. Clin Pharmacol Ther 102(3):547–553
doi: 10.1002/cpt.674
pubmed: 28224612
Matsuo M, Ito H, Takemura Y et al (2017) Increased risk of paclitaxel-induced peripheral neuropathy in patients using clopidogrel: a retrospective pilot study. J Anesth 31(4):631–635
doi: 10.1007/s00540-017-2362-y
pubmed: 28451807
Wilkinson DG (2001) Multiple roles of EPH receptors and ephrins in neural development. Nat Rev Neurosci 2(3):155–164
doi: 10.1038/35058515
pubmed: 11256076
Chhibber A, Mefford J, Stahl EA et al (2014) Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). Pharm J 14(4):336–342
Schneider BP, Li L, Miller K, et al. (2011) Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. ASCO Meeting Abstract 29(15_suppl):1000.
Bergmann TK, Vach W, Feddersen S et al (2012) GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta Oncol 52(4):871–874 1–3
doi: 10.3109/0284186X.2012.707787
pubmed: 22877241
Schneider BP, Lai D, Shen F et al (2016) Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans. Oncotarget. 7(50):82244–82253
doi: 10.18632/oncotarget.12545
pubmed: 27732968
pmcid: 5347688
Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE et al (2018) Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. Pharmacogenet Genomics 28(2):49–55
doi: 10.1097/FPC.0000000000000318
pubmed: 29278617
pmcid: 5824720
Leblanc AF, Sprowl JA, Alberti P et al (2018) OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest 128(2):816–825
doi: 10.1172/JCI96160
pubmed: 29337310
pmcid: 5785270
Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R (2007) Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J Clin Oncol 25(29):4528–4535
doi: 10.1200/JCO.2006.10.4752
pubmed: 17925548
Hertz DL, Owzar K, Lessans S et al (2016) Pharmacogenetic discovery in CALGB (Alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy. Clin Cancer Res 22(19):4890–4900
doi: 10.1158/1078-0432.CCR-15-2823
pubmed: 27143689
pmcid: 5050068
Lenk GM, Szymanska K, Debska-Vielhaber G et al (2016) Biallelic mutations of VAC14 in pediatric-onset neurological disease. Am J Hum Genet 99(1):188–194
doi: 10.1016/j.ajhg.2016.05.008
pubmed: 27292112
pmcid: 5005439
Garcia-Sanz R, Corchete LA, Alcoceba M et al (2017) Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. Hematol Oncol 35(4):746–751
doi: 10.1002/hon.2337
pubmed: 27605156
Richardson PG, Schlossman RL, Weller E et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 100(9):3063–3067
doi: 10.1182/blood-2002-03-0996
pubmed: 12384400
Anderson KC (2005) Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol 42(4 Suppl 4):S3–S8
doi: 10.1053/j.seminhematol.2005.10.001
pubmed: 16344099
Ng T, Chan M, Khor CC, Ho HK, Chan A (2014) The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: a systematic review. Cancer Treat Rev 40(10):1199–1214
doi: 10.1016/j.ctrv.2014.10.001
pubmed: 25458605
Themistocleous AC, Crombez G, Baskozos G, Bennett DL (2018) Using stratified medicine to understand, diagnose, and treat neuropathic pain. Pain. 159(Suppl 1):S31–S42
doi: 10.1097/j.pain.0000000000001301
pubmed: 30113945
pmcid: 6130809
Little J, Higgins JP, Ioannidis JP et al (2009) STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med 6(2):e22
doi: 10.1371/journal.pmed.1000022
pubmed: 19192942
Backshall A, Sharma R, Clarke SJ, Keun HC (2011) Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. Clin Cancer Res: an official journal of the American Association for Cancer Research 17(9):3019–3028
doi: 10.1158/1078-0432.CCR-10-2474
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126(4):663–676
doi: 10.1016/j.cell.2006.07.024
pubmed: 16904174
Hu S, Huang KM, Adams EJ, Loprinzi CL, Lustberg MB (2019) Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res
de Andres-Galiana EJ, Fernandez-Martinez JL, Sonis ST (2016) Sensitivity analysis of gene ranking methods in phenotype prediction. J Biomed Inform 64:255–264
doi: 10.1016/j.jbi.2016.10.012